The Association of Bacillus Calmette-Guerin Instillation Therapy Side Effects for Non Muscle-Invasive Bladder Cancer and Its Therapeutic Efficacy


  • Weelak Lerdpraiwan Division of Urology, Department of Surgery, Phramongkutklao Hospital
  • Satit Siriboonrid Division of Urology, Department of Surgery, Phramongkutklao Hospital


Bacillus Calmette-Guerin, instillation therapy, side effects, non muscle-invasive, bladder cancer


Objectives: To investigate the relation between side effects of intravesical Bacillus Calmette-Guerin (BCG) therapy and its therapeutic efficacy.

Methods: Non-muscle invasive bladder cancer patients in Phramongkutklao hospital between 2002 and 2006 who were treated with Transurethral resection of bladder tumor (TUR-BT) and intravesical instillation of BCG (completion of at least 6 times of weekly induction after TUR-BT) were analyzed. Their medical records, pathological reports and treatment protocols were reviewed retrospectively. The association between the occurrence of side effects of Bacillus Calmette-Guerin (BCG) therapy and tumor recurrence or tumor progression were analyzed.

Results: BCG side effects were occurred in 74.5% of patients. In patients with side effects, tumor recurrence was 35.6% and tumor progression was 7%.In patient without side effects, tumor recurrence was 28% and tumor progression was 20%.The occurrence of side effects was not associated with tumor recurrence and tumor progression (p-value 0.595, 0.190 respectively).

Conclusions: While a correlation between BCG side effect and efficacy exists, this study does not confirm that BCG side effect is actually responsible for an improved outcome.


Sylvester RJ, van der Meijden APM, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168:1964-70.

Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003; 169:90-5.

Lamm DL, Steg A, Boccon-Gibod L, Morales A, Hanna Jr MG, Pagano F, et al. Complications of bacillus Calmette-Guerin immunotherapy: Review of 2602 patients and comparison of chemotherapy complications. Prog Clin Biol Res 1989; 335-55.

Lamm DL, Blumenstein BA, Crawford DE, Montie JE, Scardino PA. A randomized trial of intravesical doxorubicin and immunotherapy with bacillus Calmette-Gue ́rin for transitional cell carcinoma of the bladder. N Eng J Med 1991; 325:1205-9.

Orihuela E, Herr HW, Pinsky CM, Whitmore WF. Toxicity of intravesical BCG and its management in patients with superficial bladder tumors. Cancer 1987; 60:326-33.

Orihuela E, Herr HW. Correlation between intravesical (IV) BCG toxicity and tumor response in patients (pts) with superficial bladder cancer. J Urol 1990; 143:341A [Abstract 612].

Luftenegger W, Ackermann DK, Futterlieb A, Kraft R, Minder CE, Nadelhaft P, et al. Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors. J Urol 1996; 155:483-7.

Saint F, Patard JJ, Irani J, Salomon L, Hoznek A, Legrand P, et al. Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer. Urology 2001; 57:617-21.

Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study. J Urol 2000; 163:1124-9.

Lamm DL, van der Meijden AP, Akaza H, Brendler C, Hedlund PO, Mizutani Y, et al. intravesical chemotherapy and immunotherapy: how do we assess their effectiveness and what are their limitations and uses? Int J Urol 1995; 2(Suppl 2):23-35.

De Reijke TM, De Boer EC, Kurth KH, Schamhart DHJ. Urinary interleukin-2 monitoring during prolonged bacillus Calmette-Guerin treatment: can it predict the optimal number of instillations. J Urol 1999; 161:67-71.

Kumar A, Dubey D, Bansal P, Mandhasi A, Naik S. Urinary interleukin-8 predicts the response of standard and low dose intravesical bacillus Calmette-Guerin (modified Danish 1331 strain) for superficial bladder cancer. J Urol 2002; 168:2232-5.

Thalmann GN, Sermier A, Rentsch C, Mohrle K, Cecchini MG, Studer UE. Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J Urol 2000; 164:2129-33.

Kelley DR, Haaff EO, Becich M, Lage J, Bauer WC, Dresner SM, et al. Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical bacillus Calmette-Guerin. J Urol 1986; 135:268-71.

Saint F, Salomon L, Quintela R, Cicco A, Hoznek A, Abbou CC, et al. Do prognostic parameters of remission versus relapse after bacillus Calmette-Guerin immunotherapy exist? Analysis of a quarter century of literature. Eur Urol 2003; 43:351-61.




How to Cite

Lerdpraiwan, W., & Siriboonrid, S. (2021). The Association of Bacillus Calmette-Guerin Instillation Therapy Side Effects for Non Muscle-Invasive Bladder Cancer and Its Therapeutic Efficacy. Insight Urology, 32(1), 1–8. Retrieved from



Original article